FLNA

10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein. "2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options to patients with TSC-related epilepsy and their f

AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company's clinical development program evaluating simufilam in TSC-related epilepsy. "We are pleased to engage with the epilepsy community at this important international meeting. This gathering has provided the op

DEF 14A - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)

Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend previously published preclinical findingsTSC-related epilepsy affects approximately 45,000 people in the U.S. AUSTIN, Texas, April 15, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of sev

AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Net loss for 2025 was $91.0 million, or $1.88 per share, compared to a net loss of $24.3 million, or $0.53 per sha